- XPhyto Therapeutics (XPHY) has been featured in a NetworkNewsAudio (NNA) broadcast regarding the status of its GMP mescaline synthesis program
- With its North American GMP mescaline synthesis program and German-based psilocybin biotechnology production underway, the first stage of XPhyto’s psychedelic medicine program is progressing on schedule
- Psychedelic compounds have emerged as a new class of drugs with the potential to improve the treatment of mental health-related medical conditions
- XPhyto Therapeutics Corp. is a bioscience accelerator focused on next-generation drug delivery, diagnostic, and new active pharmaceutical ingredient investment opportunities
- XPhyto Therapeutics Corp. (XPHY) is up 5 per cent, trading at C$2.10 per share at 11:30 am ET
XPhyto Therapeutics (XPHY) has been featured in a NetworkNewsAudio (NNA) broadcast.
The audio press release covers XPhyto’s recent announcement regarding the status of its GMP mescaline synthesis program.
“With both its North American GMP mescaline synthesis program and German-based psilocybin biotechnology production underway, the first stage of XPhyto’s psychedelic medicine program is progressing on schedule.
As the manufacturing programs advance, we look forward to focusing our expertise on psychedelic drug formulation,” said Hugh Rogers, CEO & Director.
“We see a significant market opportunity in the production of pharmaceutical grade psychedelics followed by the standardization of dosage formulations with precise, predictable and efficient drug delivery for clinical study and therapeutic use.”
Psychedelic compounds have emerged as a new class of drugs with the potential to improve the treatment of mental health-related medical conditions such as depression, anxiety, addiction, and trauma-related stress disorder.
Mescaline (3,4,5-trimethoxyphenethylamine) is a naturally occurring psychedelic compound found in certain cacti, such as peyote. Naturalistic use of mescaline is associated with self-reported psychiatric improvements and enduring positive life changes. Of the respondents reporting histories of depression, anxiety, post-traumatic stress disorder (PTSD), and alcohol and drug use disorders (AUD and DUD), most (68-86%) reported subjective improvement following their most memorable mescaline experience.
XPhyto Therapeutics Corp. is a bioscience accelerator focused on next-generation drug delivery, diagnostic, and new active pharmaceutical ingredient investment opportunities, including precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral health screening tests; and standardization of emerging active pharmaceutical ingredients for neurological applications, including psychedelic compounds and cannabinoids.
The company has research and development operations in North America and Europe, with an operational focus in Germany, and is currently focused on regulatory approval and commercialization of medical products for European markets.
XPhyto Therapeutics Corp. (XPHY) is up 5 per cent, trading at C$2.10 per share at 11:30 am ET.